{
  "meta": {
    "title": "Tumor_Markers_Mini_Test_-_Tmt",
    "url": "https://brainandscalpel.vercel.app/tumor-markers-mini-test-tmt-a23a40cf.html",
    "scrapedAt": "2025-11-30T12:47:18.394Z"
  },
  "questions": [
    {
      "text": "A woman was diagnosed to have metastatic liver adenocarcinoma with CK 7 (+) and CK20 (-) IHC markers. Which of the following is the most likely primary site of origin for this metastasis?",
      "choices": [
        {
          "id": 1,
          "text": "Lung carcinoma"
        },
        {
          "id": 2,
          "text": "Colorectal Carcinoma"
        },
        {
          "id": 3,
          "text": "Renal cell carcinoma"
        },
        {
          "id": 4,
          "text": "Cholangiocarcinoma"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The most likely origin of metastasis is <strong>lung carcinoma, </strong>as the IHC of the metastatic tumor revealed CK 7 (+) and CK20 (-).</p>\n<p>Cytokeratin profiles of various primary tumors:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p>        CK 7 Positive</p>\n<p>        CK 20 Positive</p>\n</td>\n<td>\n<ul>\n<li><strong>Cholangiocarcinoma</strong></li>\n<li>Ovarian mucinous carcinoma</li>\n<li>Transitional cell carcinoma</li>\n<li>Pancreatic adenocarcinoma</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>        CK 7 <strong>Positive </strong></p>\n<p>        CK 20 <strong>Negative</strong></p>\n</td>\n<td>\n<ul>\n<li>Breast carcinoma</li>\n<li>Ovarian serous adenocarcinoma</li>\n<li>Thyroid carcinoma</li>\n<li><strong>Lung carcinoma</strong></li>\n<li>Thymoma</li>\n<li>Endometrial carcinoma</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>        CK 7 Negative</p>\n<p>        CK 20 Positive</p>\n</td>\n<td>\n<ul>\n<li><strong>Colorectal adenocarcinoma</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>        CK 7 Negative</p>\n<p>        CK 20 Negative</p>\n</td>\n<td>\n<ul>\n<li>Hepatocellular carcinoma</li>\n<li><strong>Renal cell carcinoma</strong></li>\n<li>Prostatic adenocarcinoma</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Role of CK7 and CK20 Markers in Tumors of Unknown Primary</h3><p>Cytokeratin is an epithelial marker. A combination of CK7 and CK20 is used to identify the organ of origin.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>CK7</strong></td>\n<td><strong>CK20</strong></td>\n<td><strong>Common Cancers</strong></td>\n</tr>\n<tr>\n<td>+</td>\n<td>\n<p>-</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>Breast,</p>\n<p>Lung,</p>\n<p>Thyroid</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>-</td>\n<td>+</td>\n<td>Colorectal</td>\n</tr>\n<tr>\n<td>-</td>\n<td>-</td>\n<td>\n<p>&nbsp;</p>\n<p>Renal</p>\n<p>Prostate</p>\n<p>Hepatocellular</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG0080",
      "difficulty": "medium"
    },
    {
      "text": "The image given below shows an H&E-stained section of a lung tumor. The immunohistochemical studies of this tumor are most likely to express which of the following tumor markers?",
      "choices": [
        {
          "id": 1,
          "text": "Alpha-fetoprotein"
        },
        {
          "id": 2,
          "text": "Calretinin"
        },
        {
          "id": 3,
          "text": "Carcinoembryonic antigen"
        },
        {
          "id": 4,
          "text": "Cytokeratins"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The above H&amp;E stained histopathological image of a lung tumor shows <strong>keratin pearls</strong> suggestive of <strong>squamous</strong> <strong>cell</strong> <strong>carcinoma</strong>. <strong>Cytokeratins</strong> are the tumor markers that are most likely to be expressed.</p>\n<p>Cytokeratins are the intermediate filaments expressed by <strong>epithelial</strong> <strong>cells</strong>. The presence of cytokeratins on immunohistochemistry suggests a carcinoma of epithelial origin. Tumors of <strong>epithelial origin</strong> include <strong>squamous cell carcinoma</strong>, basal cell carcinoma, malignant melanoma etc.</p>\n<p>Squamous cell carcinoma of the lung is commonly seen in men and has an increased risk with smoking. The tumor appears like a cauliflower-like mass that is gray-white, firm to hard, and bulky with hemorrhage or necrosis.&nbsp;Histopathological features include keratinization in the form of <strong>squamous pearls. </strong>The cells have eosinophilic cytoplasm.</p>\n<p>Other options:</p>\n<p>Option A:<strong> Alpha-fetoprotein</strong> is a marker for <strong>hepatocellular carcinoma</strong> and<strong> non-seminomatous germ cell tumors</strong> of the testis.&nbsp;</p>\n<p>Option B: <strong>Calretinin</strong> serves as a marker for <strong>mesothelioma.</strong></p>\n<p>Option C:<strong> Carcinoembryonic</strong> <strong>antigen</strong> (CEA) is a marker for <strong>colon</strong> carcinoma and other malignancies including the&nbsp;<strong>pancreas, stomach</strong>, and <strong>heart.&nbsp;</strong></p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/e539f02914254a399461c5a6f685ca8e.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0270",
      "difficulty": "medium"
    },
    {
      "text": "A 50-year-old postmenopausal woman presented to the clinic with a history of a lump in her right breast for six months. Radiological examination showed an irregular spiculated lesion of 8 mm with microcalcification. A biopsy was taken, and the immunohistochemistry results revealed that the cell membrane was stained brown. Identify the pathophysiological mechanism of the underlying condition.",
      "choices": [
        {
          "id": 1,
          "text": "ERBB2 gene amplification"
        },
        {
          "id": 2,
          "text": "Point mutation of JAK2 receptor gene"
        },
        {
          "id": 3,
          "text": "Point mutation of EGFR tyrosine kinase"
        },
        {
          "id": 4,
          "text": "N-myc amplification"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The mechanism of neoplasia(underlying condition) here is due to the <strong>amplification</strong> of the <strong>ERBB2</strong> gene, resulting in <strong>abnormal</strong> <strong>HER2neu</strong> <strong>receptors</strong>.</p>\n<p>The given clinical stem is suggestive of <strong>invasive breast carcinoma</strong>. The radiological imaging with irregular, spiculated margins and microcalcifications is an indication for biopsy for further assessment. In the <strong>immunohistochemistry studies, </strong>the cell membrane is stained <strong>brown</strong>, indicating a <strong>HER2neu</strong>-<strong>positive tumour.</strong> <strong>Fluorescent in situ hybridisation (FISH)</strong> can be used adjunctively to confirm the diagnosis. HER2-positive is the second most common molecular subtype of invasive breast cancer.</p>\n<p>HER2 receptors (also known as ERBB2) is a receptor tyrosine kinase that promotes cell proliferation and opposes apoptosis by stimulating the RAS- and PI3K-AKT signalling pathways. </p>\n<p><strong>Immunohistochemistry staining of breast carcinoma - </strong></p>\n<ul>\n<li>The <strong>Estrogen receptor (ER)</strong> and<strong> Progesterone receptor (PR)</strong> are nuclear receptors, and the <strong>nucleus</strong> is stained brown.</li>\n<li>The<strong> human epidermal growth factor receptor type 2 (HER2)</strong> is a membrane receptor. Hence, the <strong>cell membrane</strong> is stained brown if positive.</li>\n</ul>\n<div class=\"ng-star-inserted\">\n<div class=\"table-responsive font-weight-light answer-scroll ng-star-inserted\">\n<p>The image below shows positive and negative staining for ER, PR, and HER2.</p>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/73585e3f88ba4281aaf80a529428b930x243x199.JPEG\" alt=\"Explanation Image\"><p><span>Other options:-</span></p>\n<p>Option B: Point mutation of the <strong>JAK2 receptor gene </strong>is seen in myeloproliferative neoplasias. </p>\n<p>Option C: <strong>EGFR</strong> belongs to the ERBB1 family of transmembrane receptor tyrosine kinase. EGFR is essential for the growth and differentiation of epithelial cells. Point mutation of this is the causative mechanism for adenocarcinoma of the lung. </p>\n<p>Option D: Gene amplification of the <strong>n-myc gene</strong> is seen in neuroblastoma.</p><hr><h3>Related Pearl: Growth Factor Receptors and Associated Tumors</h3><p><strong>Growth factor receptors and Associated Tumors</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p>Category</p>\n</td>\n<td>\n<p><em>Proto-Oncogene</em></p>\n</td>\n<td>\n<p>Mode of activation</p>\n</td>\n<td>\n<p>Associated tumor</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>EGF-receptor family</p>\n</td>\n<td>\n<p><em>ERBB1 (EGFR)</em></p>\n<p><em>ERBB2 (HER)</em></p>\n</td>\n<td>\n<p>Mutation</p>\n<p>Amplification</p>\n</td>\n<td>\n<p>Adenocarcinoma of lung</p>\n<p>Breast carcinoma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>FMS- like tyrosine kinase 3</p>\n</td>\n<td>\n<p><em>FLT3</em></p>\n</td>\n<td>\n<p>Point mutation</p>\n</td>\n<td>\n<p>Leukemia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Receptor for neurotrophic factors</p>\n</td>\n<td>\n<p><em>RET</em></p>\n</td>\n<td>\n<p>Point mutation</p>\n</td>\n<td>\n<p>Multiple endocrine neoplasia 2A and B, familial medullary thyroid carcinoma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>PDGF receptor</p>\n</td>\n<td>\n<p><em>PDGFRB</em></p>\n</td>\n<td>\n<p>Overexpression, translocation</p>\n</td>\n<td>\n<p>Gliomas, leukemias</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Receptor for KIT ligand</p>\n</td>\n<td>\n<p><em>KIT</em></p>\n</td>\n<td>\n<p>Point mutation</p>\n</td>\n<td>\n<p>Gastrointestinal stromal tumors, seminomas, leukemias</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>ALK receptors</p>\n</td>\n<td>\n<p><em>ALK</em></p>\n</td>\n<td>\n<p>Translocation, fusion gene formation</p>\n<p>Point mutation</p>\n</td>\n<td>\n<p>Adenocarcinoma of lung, certain lymphomas</p>\n<p>Neuroblastoma</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Molecular classification of breast cancer</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Molecular subtypes&nbsp;</strong></td>\n<td>\n<p><strong>Receptor status </strong></p>\n</td>\n<td><strong>Histological subtypes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal A type&nbsp;</strong></p>\n<p><strong>(most common,&nbsp;</strong>best prognosis)</p>\n<p>Mutated gene-&nbsp;BRCA 2</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>&lt;14% (low)</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1069\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Lobular carcinoma</p>\n<p>Mucinous carcinoma</p>\n<p>Tubular carcinoma</p>\n<p>Papillary carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal B type (HER2/neu negative)</strong></p>\n<p>Mutated gene-&nbsp;BRCA 2&nbsp;</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>&gt;14% (high)</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1064\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Poorly differentiated, lobular-carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal B type (HER2 positive)</strong></p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- +ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>variable</strong></p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><strong>HER2 enriched</strong></p>\n<p>Mutated gene-&nbsp;TP53</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;-ve</p>\n<p>Her2- +ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>High&nbsp;</strong></p>\n</td>\n<td>\n<p>Apocrine carcinoma</p>\n<p>Micro-papillary carcinoma</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Basal type&nbsp;</strong><strong>(Triple-negative)</strong></p>\n<p>Mutated gene-&nbsp;BRCA 1</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;-ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>High</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1064\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Medullary carcinoma</p>\n<p>Adenoid cystic carcinoma</p>\n<p>Secretory carcinoma</p>\n<p>Metaplastic carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>*Update: <strong>Claudin low-molecular subtype</strong>&nbsp;is a triple-negative breast cancer with low expression of E-cadherin, with a poor prognosis. It is frequently associated with lymphocyte infiltration.</p>\n<p>Almost all breast malignancies are adenocarcinomas and based on the expression of estrogen receptor and HER2 can be divided into three major biologic subgroups:</p>\n<ul>\n<li><strong>ER-positive HER2-negative tumors&nbsp;</strong>(50% to 65% of tumors) &ndash; range from well-differentiated cancers with low proliferative rates and few chromosomal changes to poorly differentiated cancers with high proliferative rates and large numbers of chromosomal rearrangements. All of these cancers express ER.</li>\n<li><strong>HER2-positive cancers - </strong>10% to 20% of tumors, which may either be ER-positive or ER-negative.</li>\n<li><strong>ER-negative, HER2-negative carcinomas&nbsp;</strong>(triple-negative or basal-like)- are characterized by genomic instability, a high proliferative rate, and expression of many proteins typical of myoepithelial cells (e.g., basal keratins).</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Defining Features</strong></p>\n</td>\n<td>\n<p><strong>ER-positive, HER2- negative</strong></p>\n&nbsp;&nbsp;</td>\n<td>&nbsp;</td>\n<td>\n<p><strong>HER2- Positive (ER- positive or negative)</strong></p>\n</td>\n<td>\n<p><strong>ER- negative</strong></p>\n<p><strong>HER2- negative</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Frequency</p>\n</td>\n<td>\n<p>~40-55% (Low proliferation)</p>\n</td>\n<td>\n<p>~10% (High proliferation)</p>\n</td>\n<td>\n<p>~20%</p>\n</td>\n<td>\n<p>~15%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Included special histologic types</p>\n</td>\n<td>\n<p>Well or moderately differentiated lobular, tubular, mucinous</p>\n</td>\n<td>\n<p>Poorly differentiated lobular</p>\n</td>\n<td>\n<p>Some apocrine</p>\n</td>\n<td>\n<p>Medullary, adenoid cystic, secretory, metaplastic</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Typical patient groups</p>\n</td>\n<td>\n<p>Older women, men, cancers detected by mammographic screening</p>\n</td>\n<td>\n<p><em>BRCA2</em> mutation carriers</p>\n</td>\n<td>\n<p>Young women, non-white women, <em>TP53</em> mutation carrier (ER-positive)</p>\n</td>\n<td>\n<p>Young women, <em>BRCA1 </em>mutation carriers, African American and Hispanic women</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF3806",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following tumor markers is least useful in assessing dysgerminoma?",
      "choices": [
        {
          "id": 1,
          "text": "Lactate dehydrogenase"
        },
        {
          "id": 2,
          "text": "Alpha-fetoprotein"
        },
        {
          "id": 3,
          "text": "Placental alkaline phosphatase"
        },
        {
          "id": 4,
          "text": "Beta-hCG"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Alpha-fetoprotein </strong>(AFP) is not a useful marker for dysgerminoma; it is a marker for <strong>endodermal sinus tumors</strong>. Dysgerminoma<strong> </strong>secretes placental alkaline phosphatase, lactate dehydrogenase (LDH), and β-hCG.</p>\n<p><strong>Dysgerminoma</strong> is a type of germ cell tumor corresponding to the testis's seminoma. It does not secrete either male or female sex hormones. It secretes <strong>placental</strong> <strong>alkaline phosphatase</strong> (ALP), <strong>lactate dehydrogenase</strong> (LDH), and <strong>β-hCG</strong>. Serum <strong>lactate dehydrogenase (LDH)</strong> is usually used to monitor these patients for disease recurrence.</p>\n<p><strong>Endodermal sinus tumor/ Yolk sac tumor </strong>is a type of ovarian germ cell tumor<strong> </strong>that is seen in premenarchal girls. <strong>Schiller-Duval bodies</strong> are pathognomonic in histopathology. <strong>Alpha-fetoprotein </strong>(AFP) is commonly produced by this tumor and is used as a tumor marker.</p><hr><h3>Related Pearl: Markers of Ovarian Neoplasm</h3><table>\n<tbody>\n<tr>\n<td><strong>Ovarian tumor</strong></td>\n<td><strong>Tumor marker</strong></td>\n<td><strong>Pathognomonic finding</strong></td>\n</tr>\n<tr>\n<td>\n<p>Epithelial ovarian tumors</p>\n</td>\n<td>CA-125,&nbsp; CA-19-9, CEA</td>\n<td>Psammoma bodies (Serous epithelial tumor)</td>\n</tr>\n<tr>\n<td>Endodermal sinus tumor</td>\n<td>AFP</td>\n<td>Schiller-Duval bodies</td>\n</tr>\n<tr>\n<td>Dysgerminoma</td>\n<td>LDH, PLAP</td>\n<td>Lymphocytic infiltration</td>\n</tr>\n<tr>\n<td>Embryonal carcinoma</td>\n<td>AFP, HCG</td>\n<td>-</td>\n</tr>\n<tr>\n<td>Mature teratoma</td>\n<td>AFP</td>\n<td>Rokitansky protruberance</td>\n</tr>\n<tr>\n<td>Granulosa cell tumor</td>\n<td>Inhibin</td>\n<td>Call&ndash;Exner bodies</td>\n</tr>\n<tr>\n<td>Hilus cell tumor</td>\n<td>-</td>\n<td>Reinke's crystal</td>\n</tr>\n<tr>\n<td>Brenner tumor</td>\n<td>-</td>\n<td>Walthard cell nest</td>\n</tr>\n<tr>\n<td>Krukenberg tumor</td>\n<td>-</td>\n<td>Signet-ring cell</td>\n</tr>\n<tr>\n<td>Clear cell tumor</td>\n<td>-</td>\n<td>Hobnail cell</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Dysgerminoma&nbsp;(Mnemonic: DPL= Delhi Premier League)</p>\n<ul>\n<li>D: Dysgerminoma</li>\n<li>P: PLAP (placental alkaline phosphatase)</li>\n<li>L: LDH (lactate dehydrogenase)</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5636",
      "difficulty": "medium"
    },
    {
      "text": "Which of these tumor markers is elevated in carcinoma breast?",
      "choices": [
        {
          "id": 1,
          "text": "CA-125"
        },
        {
          "id": 2,
          "text": "CA-19-9"
        },
        {
          "id": 3,
          "text": "CA-15-3"
        },
        {
          "id": 4,
          "text": "CA-72-4"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>CA-15-3</strong> is elevated in <strong>carcinoma breast</strong>.</p>\n<p>Tumor markers play a crucial role in <strong>identifying cancer</strong> and are often beneficial for monitoring a tumor's reaction to <strong>treatment</strong> and detecting its <strong>recurrence</strong>.</p><hr><h3>Related Pearl: Tumor Markers</h3><p><strong>Tumor Markers</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Tumor Markers</strong></p>\n</td>\n<td>\n<p><strong>Tumor Types</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Hormones</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Human chorionic gonadotropin</p>\n</td>\n<td>\n<p>Trophoblastic tumors, nonseminonmatous testicular tumors</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Calcitonin</p>\n</td>\n<td>\n<p>Medullary carcinoma of thyroid</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Catecholamine and metabolites</p>\n</td>\n<td>\n<p>Pheochromocytoma and related tumors</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Oncofetal Antigens</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&alpha;-Fetoprotein</p>\n</td>\n<td>\n<p>Liver cell cancer, nonseminonmatous germ-cell tumors of the&nbsp;testis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Carcinoembryonic antigen</p>\n</td>\n<td>\n<p>Carcinomas of the colon, lung, stomach, and heart</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Enzymes</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Prostatic acid phosphatase</p>\n</td>\n<td>\n<p>Prostate cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Neuron-specific enolase</p>\n</td>\n<td>Small-cell cancer of the lung, neuroblastoma</td>\n</tr>\n<tr>\n<td>\n<p>Lactate dehydrogenase (LDH)</p>\n</td>\n<td>Germ-cell tumors, lymphomas, leukemias</td>\n</tr>\n<tr>\n<td>Thymidine kinase</td>\n<td>Leukemias</td>\n</tr>\n<tr>\n<td>Pyruvate kinase</td>\n<td>Renal cell carcinoma</td>\n</tr>\n<tr>\n<td>Placental alkaline phosphatase</td>\n<td>Seminoma</td>\n</tr>\n<tr>\n<td>\n<p><strong>Specific Proteins</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Immunoglobulins</p>\n</td>\n<td>\n<p>Multiple myeloma and other gammopathies</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Prostate-specific antigen and prostate- specific membrane antigen</p>\n</td>\n<td>\n<p>Prostate cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>NMP 22</p>\n</td>\n<td>\n<p>Bladder cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Mucins and Other Glycoproteins</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>CA-125</p>\n</td>\n<td>\n<p>Ovarian cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>CA- 19-9</p>\n</td>\n<td>\n<p>Colon cancer, pancreatic cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>CA-15-3</p>\n</td>\n<td>\n<p>Breast cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Cell-Free DNA markers</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53, APC, RAS</em> mutants in stool and serum</p>\n</td>\n<td>\n<p>Colon cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53, RAS</em> mutants in stool and serum</p>\n</td>\n<td>\n<p>Pancreatic cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53, RAS</em> mutants in sputum and serum</p>\n</td>\n<td>\n<p>Lung cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53</em> mutants in urine</p>\n</td>\n<td>\n<p>Bladder cancer</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>NMP: Nuclear matrix protein</p>\n<p>CA: Carbohydrate antigen</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4330",
      "difficulty": "medium"
    },
    {
      "text": "A 30-year-old female was diagnosed with thyroid carcinoma. The histopathological image is shown below. Which of the following is correct regarding the management of this subtype of thyroid carcinoma?",
      "choices": [
        {
          "id": 1,
          "text": "Prophylactic neck dissection is not indicated"
        },
        {
          "id": 2,
          "text": "Paclitaxel is the drug of choice for metastatic disease"
        },
        {
          "id": 3,
          "text": "Postoperative management includes Radioactive Iodine Ablation (RAI)"
        },
        {
          "id": 4,
          "text": "Calcitonin and CEA levels testing are used for the follow-up"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The histopathology image shows <strong>amyloid-rich stroma</strong> and spindle cells, which are characteristic of <strong>Medullary Thyroid Carcinoma (MTC).</strong> <strong>Calcitonin</strong> and <strong>CEA</strong> are used for the <strong>follow-up</strong> of Medullary Thyroid Carcinoma (MTC) patients. </p>\n<p>Medullary Thyroid Carcinoma (MTC) arises from the <strong>parafollicular </strong>or<strong> C cells</strong> of the thyroid, which are concentrated <strong>superolateral</strong> in the thyroid and are derived from the <strong>neural crest</strong>. MTC usually occurs in a <strong>sporadic</strong> form (80%). It can also occur as inherited syndromes such as <strong>Familial MTC, MEN2A, </strong>and <strong>MEN2B</strong>. All these variants are associated with germline mutations in the <strong>RET proto-oncogene.</strong></p>\n<p>Clinical features of Medullary Thyroid Carcinoma (MTC) include,</p>\n<ul>\n<li aria-level=\"1\"><strong>50-60 years</strong> of age (<strong>younger</strong> age in <strong>familial</strong> MTC)</li>\n<li aria-level=\"1\">Mostly <strong>unilateral</strong> (<strong>bilateral</strong> and <strong>multicentric</strong> in<strong> familial</strong> MTC) </li>\n<li aria-level=\"1\"><strong>Palpable mass</strong> in the thyroid</li>\n<li aria-level=\"1\"><strong>Cervical lymphadenopathy</strong> is common</li>\n<li aria-level=\"1\">Hematogenous spread is also seen. The most common distant metastasis is seen in <strong>Liver</strong> &gt; Bones (<strong>osteoblastic</strong>).</li>\n<li aria-level=\"1\">Dysphagia, dyspnea, or dysphonia (due to local invasion)</li>\n<li aria-level=\"1\"><strong>Diarrhea</strong> may occur in 30% of cases (due to <strong>5-hydroxytryptamine</strong> or<strong> prostaglandins</strong> secreted by tumour cells)</li>\n<li aria-level=\"1\">Some develop <strong>Cushing’s</strong> syndrome (due to <strong>ectopic adrenocorticotropic hormone</strong>)</li>\n</ul>\n<p>Medullary Thyroid Carcinoma (MTC) secretes <strong>calcitonin, carcinoembryonic antigen (CEA)</strong>, and other peptides such as <strong>calcitonin gene-related</strong> <strong>peptides, serotonin, prostaglandins E2 and F2α, </strong>and<strong> histaminadases.</strong></p>\n<p><strong>Diagnosis</strong> is made based on the <strong>clinical features</strong>, <strong>raised serum calcitonin</strong>, or <strong>CEA</strong> levels, and <strong>FNAB</strong> cytology.</p>\n<p>All<strong> new patients</strong> with MTC should be <strong>screened for</strong> <strong>RET</strong> point mutations, <strong>pheochromocytoma</strong>, and <strong>hyperparathyroidism</strong>. If patients are found to have a pheochromocytoma, it must be treated first.</p>\n<p><strong>Pentagastrin</strong> (synthetic gastrin analogue), which<strong> increases</strong> the basal rate of <strong>calcitonin</strong> secretion, was formerly used to screen patients with Familial Medullary Thyroid Carcinoma (MTC). <strong>RET testing</strong> has replaced <strong>pentagastrin</strong> or <strong>calcium-stimulated calcitonin</strong> levels testing in the screening of patients with familial MTC.</p>\n<p><strong>Management</strong> of Medullary Thyroid Carcinoma (MTC) is as follows:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Extent of cancer</strong></td>\n<td><strong>Surgery </strong></td>\n</tr>\n<tr>\n<td>\n<p>MTC without LN involvement</p>\n</td>\n<td>Total thyroidectomy + <strong>Central neck dissection (prophylactic)</strong>(Option A)</td>\n</tr>\n<tr>\n<td>\n<p>MTC + <strong>central neck nodes</strong> involved or tumor size <strong>≥1.5 cm</strong></p>\n</td>\n<td>Total thyroidectomy + Central neck dissection (therapeutic) +<strong> Ipsilateral Modified radical neck dissection (prophylactic)</strong></td>\n</tr>\n<tr>\n<td>\n<p>MTC + <strong>other LNs i</strong>nvolved</p>\n</td>\n<td>Total thyroidectomy + Central neck dissection + <strong>Bilateral Modified radical neck dissection (therapeutic)</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Metastatic</strong> disease</p>\n</td>\n<td>\n<p> </p>\n<ul>\n<li><strong>Debulking thyroidectomy</strong></li>\n<li><strong>Chemotherapy</strong> -</li>\n</ul>\n<ul>\n<ul>\n<li><strong>Vandetanib </strong>(multi-kinase inhibitor) - <strong>drug of choice </strong></li>\n<li>Labetuzumab (anti-CEA)</li>\n</ul>\n</ul>\n<ul>\n<li>External beam radiotherapy</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>There is no role of <strong>Radioactive Iodine Ablation (RAI) </strong>(Option C) in MTC as the tumor is not TSH-dependent and doesn’t take up radioactive iodine.</p>\n<p><strong>Annual calcitonin </strong>and <strong>CEA</strong> level testing is used for the <strong>follow-up</strong> of Medullary Thyroid Carcinoma (MTC) patients. Imaging (USG/CT neck and mediastinum, FDG-PET/CT scans) is also useful.</p>\n<p>Other options:</p>\n<p>Option B - <strong>Paclitaxel</strong> is used for adjunctive chemotherapy (Adriamycin + Paclitaxel/Cisplatin) in Anaplastic thyroid carcinoma (ATC). It is not a valid chemotherapy option for Medullary Thyroid Carcinoma (MTC).</p><hr><h3>Related Pearl: MEN 2 Syndrome Features</h3><p><strong>MEN 2A</strong></p>\n<ul>\n<li>Known as <strong>Sipple&rsquo;s</strong> syndrome</li>\n<li>Chromosome <strong>10</strong> / <strong>RET gene</strong></li>\n<li>Associated conditions are:\n<ul>\n<li>Medullary Thyroid Carcinoma (90%)</li>\n<li>Pheochromocytoma (&gt;50%)</li>\n<li>Parathyroid adenoma (10&ndash;25%)</li>\n</ul>\n</li>\n</ul>\n<p><strong>MEN 2B</strong></p>\n<ul>\n<li>Known commonly as<strong> MEN 3</strong></li>\n<li>Chromosome<strong> 10/ RET gene</strong></li>\n<li>Associated conditions are:\n<ul>\n<li>Medullary Thyroid Carcinoma (&gt;90%)</li>\n<li>Pheochromocytoma (&gt;50%)</li>\n<li>Other associated abnormalities include: (40&ndash;50%)\n<ul>\n<li>Mucosal neuromas</li>\n<li>Marfanoid habitus</li>\n<li>Medullated corneal nerve fibers</li>\n<li>Megacolon</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a01742751e314b5fb189a29264e911d3x1280x1061.JPEG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/35f2dce4dbbe4001b0f8332a78aaab16.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5298",
      "difficulty": "medium"
    },
    {
      "text": "A 65-year-old patient was found to have a PSA  of 5.6 ng/ml on routine examination and was advised to undergo a TRUS-guided transrectal biopsy. What is the standard biopsy template?<div class='question-desc-html'><p>TRUS-Trans Rectal Ultrasound Scan</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "6 biopsies form 3 areas"
        },
        {
          "id": 2,
          "text": "6 biopsies from 6 areas"
        },
        {
          "id": 3,
          "text": "12 biopsies from 6 areas"
        },
        {
          "id": 4,
          "text": "12 biopsies from 12 areas"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The standard biopsy template usually includes <strong>12 biopsies taken from six areas.</strong></p>\n<p class=\"p1\">Patients who have either an <strong>elevated total PSA level</strong> (i.e. over 2.5 - 4.0 ng/ml) or <strong>abnormal findings</strong> on digital rectal examination (<strong>DRE</strong>) <strong>or both</strong> are advised to undergo <strong>TRUS-guided biopsy</strong> of the prostate.</p>\n<p class=\"p1\">The standard biopsy template involves <strong>12 core biopsies</strong> with a spring-loaded biopsy instrument.</p>\n<p class=\"p1\"><strong>Site of biopsy</strong>: The tissue is usually obtained from the <strong>base, mid,</strong> and <strong>apex</strong> regions, medially and laterally from the left and right sides.</p>\n<p class=\"p1\">Patients are asked to <strong>stop anticoagulants</strong> to prevent bleeding complications.</p>\n<p class=\"p1\">Common <strong>adverse effects</strong> that follow TRUS biopsy include rectal bleeding, gross hematuria, and hematospermia, all of which are usually self-limited. Fever, urinary infection and retention occur in less than 5% of patients.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4023",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old man presents with complaints of fatigue, pain over the ribs, and confusion. Laboratory investigations reveal anemia, hypercalcemia, and increased serum creatinine level. The peripheral smear shows the finding given below. The international prognostic staging system for this disease is based on the levels of which of the following parameters?",
      "choices": [
        {
          "id": 1,
          "text": "β2 microglobulin and albumin"
        },
        {
          "id": 2,
          "text": "β2 microglobulin and serum creatinine"
        },
        {
          "id": 3,
          "text": "β2 glycoprotein and plasma light chains"
        },
        {
          "id": 4,
          "text": "β2 glycoprotein and serum creatinine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The clinical scenario and peripheral smear showing a <strong>Mott cell</strong> suggest a probable diagnosis of <strong>multiple myeloma. </strong>The international prognostic staging system for multiple myeloma is based on<strong> </strong>levels of<strong> β2 microglobulin and albumin.</strong></p>\n<p><strong>Mott cells </strong>are plasma cells with globular <strong>cytoplasmic inclusions</strong> containing <strong>immunoglobulins</strong> called <strong>Russell bodies</strong>. They may be seen in African trypanosomiasis and multiple myeloma.</p>\n<p>Multiple myeloma is a <strong>plasma cell dyscrasia</strong> in which there is an <strong>unregulated proliferation of plasma cells</strong>. The proliferating cells stimulate osteoclastic activity and suppress osteoblastic activity, leading to the formation of <strong>multiple lytic bone lesions</strong>. These lesions can be seen on radiographs as '<strong>punched out' lesions.</strong>  In some severe cases, patients may present with pathological fractures. </p>\n<p>Other features of multiple myeloma:</p>\n<ul>\n<li aria-level=\"1\">Acute renal failure in a dehydrated state</li>\n<li aria-level=\"1\"><strong>Normocytic normochromic anemia</strong> </li>\n<li aria-level=\"1\"><strong>Hyperviscosity syndromes</strong> cause headache, exacerbation, or precipitation of heart failure, <strong>visual disturbances</strong>, ataxia, and vertigo</li>\n<li aria-level=\"1\">Bony damage leading to cord compression</li>\n<li aria-level=\"1\">Carpal tunnel syndrome</li>\n<li aria-level=\"1\"><strong>Sensory</strong> more than motor <strong>neuropathy</strong> associated with IgM directed against myelin-associated globulin</li>\n</ul>\n<p>The single <strong>most important predictor</strong> for <strong>survival</strong> is <strong>serum β<sub>2</sub>-microglobulin</strong>. <strong>Serum β<sub>2</sub>-microglobulin</strong>, along with <strong>serum albumin,</strong> forms the basis of the <strong>International Staging System</strong> for multiple myeloma that <strong>predicts survival</strong>.</p>\n<p><strong>International Staging System (ISS) for multiple myeloma:</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>β2 microglobulin (mg/dL) and albumin (g/dL) level</strong></td>\n<td>Stage</td>\n<td>Median survival months</td>\n</tr>\n<tr>\n<td>\n<p>β2M &lt; 3.5</p>\n<p>alb ≥3.5</p>\n</td>\n<td>I</td>\n<td>62</td>\n</tr>\n<tr>\n<td>\n<p>β2M &lt; 3.5, alb &lt; 3.5</p>\n<p>or β2M = 3.5-5.5</p>\n</td>\n<td>II</td>\n<td>44</td>\n</tr>\n<tr>\n<td>β2M &gt; 5.5</td>\n<td>III</td>\n<td>29</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p><hr><h3>Related Pearl: Prognostic Factors in Myeloma</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Poor prognosis</strong></p>\n</td>\n<td>\n<p><strong>Good prognosis</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>t(4;14), MAF translocations t(14;16) and t(14;20), del(17p), aneuploidy, hypodiploidy</p>\n</td>\n<td>\n<p>Hyperdiploid, t(11;14), t(6;14), cyclin D1 or D3 positive</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Elevated beta-2 microglobulin, lactate dehydrogenase, C- reactive protein, plasma-cell proliferation, or bone marrow infiltration</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Plasmablastic morphology</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Abnormalities by conventional cytogenetics</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Plasma labelling index &gt;3%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Serum creatinine level &gt;2mg/dL</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Bone marrow biopsy: Diffuse&nbsp;and prominent angiogenesis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Low serum albumin</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/f188e13156464995a0790b62297e4944.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7042",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is not a marker for gastrointestinal stromal tumors?<br><br>\n",
      "choices": [
        {
          "id": 1,
          "text": "KIT"
        },
        {
          "id": 2,
          "text": "SDH"
        },
        {
          "id": 3,
          "text": "PDGFRA"
        },
        {
          "id": 4,
          "text": "NRG-1"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>NRG-1</strong> (Neuregulin-1) is not a marker for <strong>gastrointestinal stromal tumors</strong> (GISTs).</p>\n<p><strong>GIST</strong> is the most common <strong>mesenchymal</strong> tumor of the <strong>abdomen,</strong> the <strong>stomach</strong> being the most common site. They arise from the <strong>interstitial cells</strong> of <strong>Cajal,</strong> the pacemaker cells of the GIT. GIST is seen in the <strong>5th</strong> to <strong>6th decade</strong> of life and has an <strong>equal preponderance</strong> among males and females. Most patients present with <strong>haematemesis, melena,</strong> or <strong>vague abdominal</strong> pain. The most common indications for surgery include <strong>bleeding</strong> and <strong>obstruction.</strong></p>\n<p>The GIST may occur in a <strong>sporadic</strong> form or as part of <strong>familial syndromes.</strong> In sporadic GIST, the most common mutations seen are gain-of-function mutation in <strong>KIT</strong> (75-80%) and <strong>PDGFRA</strong> mutation (8%). Succinate dehydrogenase (<strong>SDH</strong>)-deficient GIST is a subset of wild-type GIST seen with Carney triad or Carney-Stratakis syndrome. </p>\n<p>The below image shows the microscopy of GIST composed of bundles, or fascicles, of spindle-shaped tumour cells.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a9bf9b67e36847358296aa149b9b4ea8x1280x1033.JPEG\" alt=\"Explanation Image\"><p><strong>Microscopically, </strong>GIST has elongated <strong>spindle</strong> cells, plumper epithelioid cells, or a mixed pattern.</p>\n<p><strong>Imatinib</strong> can be used to treat GIST with mutations in <strong>KIT</strong> or <strong>PDGFRA.</strong> Succinate dehydrogenase (SDH) - deficient GIST is imatinib-resistant, so sunitinib, sorafenib, or regorafenib can be used instead. </p>\n<p>During surgical resection of GIST, care must be taken to prevent capsule rupture, which causes <strong>seeding</strong> of <strong>nearby tissues</strong> leading to <strong>relapse</strong> in <strong>100%</strong> of the <strong>cases.</strong> If capsule rupture occurs, adjuvant therapy with imatinib is indicated regardless of tumor extent.</p>\n<p>Other options:</p>\n<p>Option A: <strong>KIT (CD117):</strong> This is the most well-known marker for GISTs. About 85% of GISTs show mutations in the KIT gene, leading to the expression of the KIT protein on the cell surface. KIT is a receptor tyrosine kinase, and its activation is a key driver in the pathogenesis of GISTs.</p>\n<p>Option B: <strong>SDH (Succinate</strong> Dehydrogenase): SDH mutations are associated with a subset of GISTs, particularly those that are KIT and PDGFRA wild-type. Loss of SDH function is characteristic of this subgroup, and SDH deficiency can be demonstrated through immunohistochemistry.</p>\n<p>Option C: <strong>PDGFRA</strong> (Platelet-Derived Growth Factor Receptor Alpha): Mutations in the PDGFRA gene account for approximately 5-10% of GISTs. Similar to KIT, PDGFRA is a receptor tyrosine kinase, and mutations in this gene can lead to the development of GISTs.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG6660",
      "difficulty": "medium"
    },
    {
      "text": "A 12-year-old child presented with complaints of fatigue, fever, and dyspnea for the past week. Chest X-ray reveals mediastinal widening. Peripheral smear findings are given below. Which of the following findings on immunophenotyping do you expect to find in this case?\n<div class='question-desc-html'><p>MPO: Myeloperoxidase<br />TdT: Terminal deoxynucleotidyl transferase<br />PAS: Periodic acid-Schiff</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "MPO positive"
        },
        {
          "id": 2,
          "text": "TdT positive"
        },
        {
          "id": 3,
          "text": "CD33 positive"
        },
        {
          "id": 4,
          "text": "PAS negative"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario of a<strong> 12-year-old </strong>child presenting with <strong>fatigue, fever,</strong> and <strong>dyspnea</strong>, a chest X-ray showing<strong> mediastinal widening</strong>, and a peripheral smear showing <strong>abundant lymphoblasts</strong> (cells with scant cytoplasm and large nucleus) is suggestive of<strong> acute lymphoblastic leukemia (ALL)</strong>. ALL will be <strong>TdT positive </strong>on immunophenotyping.</p>\n<p><strong>ALL</strong> is the most<strong> common cancer in childhood</strong>. <strong>B-cell ALLs</strong> usually present as <strong>early childhood leukemias,</strong> while <strong>T-cell ALLs </strong>are usually seen in <strong>adolescents </strong>as <strong>thymic lymphomas.</strong> Clinical features include <strong>fatigue, infections, bleeding diathesis</strong> (due to impaired marrow function), <strong>hepatosplenomegaly, fever</strong>, and <strong>dyspnea</strong> due to mediastinal or thymic infiltration.</p>\n<p>Initial evaluation involves a<strong> routine complete blood count</strong> and<strong> peripheral smear</strong>. It typically reveals<strong> anemia, thrombocytopenia, </strong>and the <strong>presence of blasts (immature WBCs) </strong>on the smear. <strong>Morphologically</strong>, myeloblasts and lymphoblasts may be<strong> difficult to distinguish</strong>.<strong> Immunophenotyping</strong> thus plays an important role in<strong> confirming</strong> the diagnosis.</p>\n<p> </p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"3\"><strong>Immunophenotyping</strong></td>\n</tr>\n<tr>\n<td> </td>\n<td><strong>ALL</strong></td>\n<td><strong>AML</strong></td>\n</tr>\n<tr>\n<td><strong>Immunohistochemistry</strong></td>\n<td>MPO negative<br />TdT positive <br />PAS positive</td>\n<td>\n<p>MPO positive<br />TdT negative <br />PAS negative</p>\n</td>\n</tr>\n<tr>\n<td><strong>Flow cytometry</strong></td>\n<td>\n<p>Pre-B cell leukemia - </p>\n<ul>\n<li>CD10 </li>\n<li>CD19 </li>\n<li>CD20 </li>\n<li>CD22</li>\n<li>Cytoplasmic IgM heavy chain (μ chain)</li>\n</ul>\n<p>Pre-T cell leukemia - </p>\n<ul>\n<li>CD1 </li>\n<li>CD2 </li>\n<li>CD5</li>\n<li>CD7</li>\n</ul>\n</td>\n<td>\n<p>Myeloid blasts - </p>\n<ul>\n<li>CD34 (a marker of multipotent stem cells) </li>\n<li>Do not express CD64 (a marker of mature myeloid cells)</li>\n<li>CD33 or CD15 in a few subsets</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>AML - Acute myelogenous leukemia</p>\n<p>Other options:</p>\n<p>Option A: <strong>MPO positive </strong>on immunohistochemistry is a feature of <strong>myeloblasts</strong> seen in <strong>AML</strong>. Lymphoblasts are MPO-negative.</p>\n<p>Option C: <strong>CD33 positive </strong>on flow cytometry is a marker of <strong>myeloid progenitors</strong> and monocytes seen in <strong>AML</strong>. </p>\n<p>Option D: <strong>PAS negative </strong>on immunohistochemistry is a feature of <strong>myeloblasts</strong> seen in <strong>AML</strong>. Lymphoblasts are usually PAS-positive. </p><hr><h3>Related Pearl: Morphological Characteristics of Blasts Cells in Acute Lymphoblastic Leukemia vs. Acute Myeloid Leukemia</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Lymphoblasts&nbsp;</strong></td>\n<td><strong>Myeloblasts</strong>&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Blast population</strong></td>\n<td>Homogeneous</td>\n<td>Heterogeneous,&nbsp;with the exception of&nbsp;the undifferentiated form&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Size</strong></td>\n<td>Variable, mainly small&nbsp;</td>\n<td>Variable, mainly large&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Nucleus</strong></td>\n<td>Central, mainly round; sometimes indented.&nbsp;<br />&nbsp;</td>\n<td>Eccentric, round, oval, or angulated; sometimes convoluted, particularly in the form with a monocytic component&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Chromatin</strong></td>\n<td>Fine, with dispersed condensation.&nbsp;<br />Very condensed in small&nbsp;lymphoblasts&nbsp;</td>\n<td>Fine, granular, delicately dispersed&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Nucleoli</strong></td>\n<td>Absent in small&nbsp;lymphoblasts.&nbsp;<br />Sometimes indistinct&nbsp;</td>\n<td>Present. Often large and prominent,&nbsp;double or triple&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Cytoplasm</strong></td>\n<td>Scanty and basophilic.<br />Sometimes with a single long projection (hand-mirror cell)&nbsp;</td>\n<td>Variable.&nbsp;<br />Abundant in&nbsp;monoblasts,&nbsp;<br />with protrusions in erythroblasts and&nbsp;megakaryoblasts&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Granules</strong></td>\n<td>Rarely present. Negative for peroxidase,&nbsp;esterases, and toluidine blue&nbsp;</td>\n<td>Present&nbsp;in forms with differentiation and positive with cytochemical stains\n<ul>\n<li data-listid=\"35\" data-aria-posinset=\"1\" data-aria-level=\"1\">Peroxidase in the neutrophil and&nbsp;eosinophil&nbsp;lineages</li>\n<li data-listid=\"35\" data-aria-posinset=\"2\" data-aria-level=\"1\">Nonspecific esterase in the monocyte lineage&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Auer rods</strong></td>\n<td>Absent&nbsp;</td>\n<td>Can be present.&nbsp;<br />Typically present in the hyper granular promyelocytic form&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Vacuoles</strong></td>\n<td>Can&nbsp;be present</td>\n<td>Can be present.&nbsp;<br />Almost always present in forms with a monocytic component&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>The image given below shows lymphoblasts.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/602336fa8d4c493297f9396f1c0723d3x720x820.JPEG\" alt=\"Pearl Image\"><p>The image given below shows myeloblasts.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b1dfcd5c07f949719ccdce6583872615x250x364.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: Immune Cell Antigens Detected by Monoclonal Antibodies</h3><table>\n<tbody>\n<tr>\n<td><strong><span class=\"TextRun SCXW86796565\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW86796565\">Antigen</span></span><span class=\"TextRun SCXW86796565\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW86796565\">&nbsp;</span></span><span class=\"TextRun SCXW86796565\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW86796565\">Designation</span></span><span class=\"TextRun SCXW86796565\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW86796565\">&nbsp;and their&nbsp;</span></span><span class=\"TextRun SCXW86796565\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW86796565\">Normal Cellular Distribution</span></span><span class=\"EOP SCXW86796565\" data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></strong></td>\n</tr>\n<tr>\n<td><strong><span class=\"TextRun SCXW130168874\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW130168874\">Primarily T-Cell Associated</span></span><span class=\"EOP SCXW130168874\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">CD1&nbsp;Thymocytes and Langerhans cells&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">CD3&nbsp;Thymocytes, mature T cells&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"3\" data-aria-level=\"1\">CD4 Helper T cells, subset of thymocytes&nbsp;&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"4\" data-aria-level=\"1\">CD5 T cells and a small subset of B cells&nbsp;&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\">CD8 Cytotoxic T cells, subset of thymocytes, and some NK cells&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong><span class=\"TextRun SCXW177769382\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW177769382\">Primarily B-Cell Associated</span></span></strong><span class=\"EOP SCXW177769382\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"4\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">CD10 Pre-B cells and germinal-center B cells&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"4\" aria-setsize=\"-1\" data-aria-posinset=\"3\" data-aria-level=\"1\">CD19 Pre-B cells and mature B cells, but not plasma cells&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"4\" aria-setsize=\"-1\" data-aria-posinset=\"4\" data-aria-level=\"1\">CD20 Pre-B cells after CD19 and mature B cells, but not plasma cells&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"4\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\">CD21 EBV receptor; mature B cells and follicular dendritic cells</li>\n</ul>\n<ul>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"4\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">CD23 Activated mature B cells&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"4\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">CD79a Marrow pre-B cells and mature B cells&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong><span class=\"TextRun SCXW5554072\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW5554072\">Primarily Monocyte or Macrophage Associated</span></span><span class=\"EOP SCXW5554072\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"6\" aria-setsize=\"-1\" data-aria-posinset=\"4\" data-aria-level=\"1\">CD11c Granulocytes, monocytes, and macrophages; also expressed&nbsp;by hairy cell leukemias&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"6\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\">CD13 Immature and mature monocytes and granulocytes&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"6\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\">CD14 Monocytes&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"6\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\">CD15 Granulocytes; Reed-Sternberg cells and variants</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"6\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\">CD33 Myeloid progenitors and monocytes&nbsp;&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"6\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\">CD64 Mature myeloid cells&nbsp;&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong><span class=\"TextRun SCXW245085851\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW245085851\">Primarily NK-CellAssociated</span></span><span class=\"EOP SCXW245085851\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"7\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">CD16 NK cells and granulocytes&nbsp;&nbsp;</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"7\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">CD56 NK cells and a subset of T cells&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong><span class=\"TextRun SCXW128063462\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW128063462\">Primarily Stem Cell and Progenitor Cell Associated </span></span></strong><span class=\"EOP SCXW128063462\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li><span class=\"TextRun SCXW128063462\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW128063462\"><span class=\"TextRun SCXW257355501\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW257355501\">CD34 Pluripotent hematopoietic stem cells and progenitor cells of many lineages</span></span><span class=\"EOP SCXW257355501\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></span></span></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong><span class=\"TextRun SCXW128063462\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW128063462\"><span class=\"TextRun SCXW237922357\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW237922357\">Activation Markers</span></span><span class=\"EOP SCXW237922357\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></span></span></strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li><span class=\"TextRun SCXW128063462\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW128063462\"><span class=\"TextRun SCXW58944318\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW58944318\">CD30 Activated B cells, T cells, and monocytes; Reed-Sternberg cells and variants</span></span><span class=\"EOP SCXW58944318\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></span></span></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><span class=\"TextRun SCXW128063462\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW128063462\"><span class=\"TextRun SCXW58944318\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW58944318\"><strong><span class=\"TextRun SCXW110477194\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW110477194\">Present on All Leukocytes</span></span></strong><span class=\"EOP SCXW110477194\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></span></span></span></span></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li><span class=\"TextRun SCXW128063462\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW128063462\"><span class=\"TextRun SCXW121164674\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW121164674\">CD45 All leukocytes; also known as leukocyte common antigen (LCA)</span></span><span class=\"EOP SCXW121164674\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;</span></span></span></li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Prognostic factors in ALL</h3><p>Prognostic factors in ALL</p>\n<table>\n<tbody>\n<tr>\n<td><strong>&nbsp;Prognostic factors</strong></td>\n<td><strong>Good</strong></td>\n<td><strong>Bad</strong></td>\n</tr>\n<tr>\n<td>Age</td>\n<td>2-9 years</td>\n<td>&lt;1 year or &gt;10 years</td>\n</tr>\n<tr>\n<td>Sex</td>\n<td>Female</td>\n<td>Male</td>\n</tr>\n<tr>\n<td>Race</td>\n<td>White</td>\n<td>Black</td>\n</tr>\n<tr>\n<td>CNS leukemia</td>\n<td>Absent</td>\n<td>Overt</td>\n</tr>\n<tr>\n<td>Hepatosplenomegaly, Lymphadenopathy</td>\n<td>Absent</td>\n<td>Massive</td>\n</tr>\n<tr>\n<td>Mediastinal mass</td>\n<td>Absent</td>\n<td>Present</td>\n</tr>\n<tr>\n<td>Testicular involvement</td>\n<td>Absent</td>\n<td>Present</td>\n</tr>\n<tr>\n<td>WBC count</td>\n<td>&lt;50,000/mm<sup>3</sup></td>\n<td>&gt;50,000/mm<sup>3</sup></td>\n</tr>\n<tr>\n<td>FAB Type</td>\n<td>L1</td>\n<td>L2,L3</td>\n</tr>\n<tr>\n<td>Cytogenetics</td>\n<td>Hyperdiploidy</td>\n<td>Hypodiploidy</td>\n</tr>\n<tr>\n<td>Immunophenotype</td>\n<td>B-cell, early pre-B</td>\n<td>T cell</td>\n</tr>\n<tr>\n<td>Translocation</td>\n<td>T(12,21),Notch 1,HOX 11</td>\n<td>t(9,22),t(4,11)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/f350ae5517e24f3bb0e55ac7dce515c5.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG1980",
      "difficulty": "medium"
    },
    {
      "text": "A 65-year-old patient came to the OPD with complaints of swelling over the cervical region. On examination, it is found to be painless lymphadenopathy along with the presence of splenomegaly. On HPE examination, the following picture given in the image is seen with the absence of centroblasts. Immunophenotyping shows CD23 negative, CD 19 and CD 20 positive.\nWhich of the following is false regarding the above condition?",
      "choices": [
        {
          "id": 1,
          "text": "Presence of t(11;14)"
        },
        {
          "id": 2,
          "text": "Increased expression of cyclin D1"
        },
        {
          "id": 3,
          "text": "Somatic hypermutation of IgH locus"
        },
        {
          "id": 4,
          "text": "Association with lymphomatoid polyposis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical and biopsy picture points to <strong>Mantle cell lymphoma,</strong> which has its origin <strong>from naïve B cells,</strong> which <strong>are characterised by a lack of somatic hypermutation</strong> <strong>of the IgH gene </strong>(Due to the tumour arising from Naive B Cells).</p>\n<p><strong>Mantle cell lymphoma : </strong></p>\n<ul>\n<li>Tumor cells resemble the normal mantle zone B- cells which surround the germinal centre</li>\n<li>Seen in the fifth and sixth decades of life</li>\n<li>Has male predominance</li>\n<li>Has (11;14) translocation (Option A)</li>\n<li>IgH locus on – chromosome 14</li>\n<li>Cyclin D1 locus on – chromosome 11</li>\n<li>Overexpression of Cyclin D1 is seen (Option B)</li>\n</ul>\n<p><strong>Features: </strong></p>\n<ul>\n<li><strong>Painless lymphadenopathy</strong></li>\n<li><strong>Splenomegaly</strong></li>\n<li>Multifocal mucosal involvement of small bowel and colon –<strong> lymphomatoid polyposis </strong>(Option D)</li>\n</ul>\n<p><strong>Histology :</strong></p>\n<ul>\n<li>Nodal tumor cells may surround reactive germinal centres to produce a nodular appearance at low power or diffusely efface the node.</li>\n<li>Typically, the proliferation consists of a<strong> homogeneous population of small lymphocytes with irregular to occasionally deeply cleft (cleaved) nuclear contours</strong></li>\n<li>Large cells resembling <strong>centroblasts and proliferation centres are absent</strong>, distinguishing mantle cell lymphoma from follicular lymphoma and CLL/SLL, respectively</li>\n</ul>\n<p><strong>Immunophenotyping :</strong></p>\n<ul>\n<li>CD 5+</li>\n<li>CD 23 negative</li>\n<li>CD19 and  CD20 positive</li>\n<li>Moderately high levels of surface Ig (usually IgM and IgD with κ or λ light chain)</li>\n<li>The IgH genes lack somatic hypermutation, supporting an origin from a naive B cell</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/d0b1f654696c4a9c88140699b22315e8.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8711",
      "difficulty": "medium"
    },
    {
      "text": "A patient presents to the OPD with a history of swelling over the anterior part of the neck, fatigue, and weight loss for two months. On examination, the mass moves with deglutition. A biopsy from the patient's thyroid gland is shown below. Investigations reveal elevated plasma metanephrines, serum calcium, PTH, and calcitonin. She also gives a history of her mother undergoing surgery for a lump in the neck many years before. Which of the following is likely to result in the above condition?",
      "choices": [
        {
          "id": 1,
          "text": "Gain of function mutation in RET"
        },
        {
          "id": 2,
          "text": " Loss of function mutation in RET"
        },
        {
          "id": 3,
          "text": "Gain of function mutation in K-RAS "
        },
        {
          "id": 4,
          "text": "Loss of function mutation in K-RAS"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical vignette describes the features of <strong>MEN 2A syndrome,</strong> which includes <strong>medullary thyroid carcinoma </strong>(The given histopathology picture shows the presence of <strong>amyloid-rich stroma</strong> and family history of thyroid surgery), <strong>parathyroid adenoma (elevated</strong> serum <strong>calcium, PTH,</strong> and calcitonin) and <strong>pheochromocytoma (elevated</strong> plasma <strong>metanephrines).</strong> The <strong>gain of function mutations</strong> in <strong>RET</strong> proto-oncogene occurs in MEN 2A syndrome.</p>\n<p>Multiple endocrine neoplasia is characterised by the presence of tumors in <strong>two </strong>or<strong> more endocrine glands. </strong>It can be MEN 1, MEN 2A, MEN 2B (MEN 3), or MEN 4.</p>\n<p>MEN <strong>1</strong> is associated mainly with <strong>parathyroid adenoma, pancreatic tumors,</strong> and<strong> pituitary tumors. </strong></p>\n<p>MEN type <strong>2</strong> comprises groups of disorders caused by gain-of-function mutations of the RET proto-oncogene at chromosomal locus 10q11.2. There are three variants:</p>\n<ul>\n<li aria-level=\"1\">MEN 2A, also known as MEN 2 (most common type)</li>\n<li aria-level=\"1\">MEN 2B, also known as MEN 3</li>\n<li aria-level=\"1\">MTC only</li>\n</ul>\n<p>MEN <strong>2A</strong> is also known as Sipple's syndrome. It is characterized by medullary thyroid carcinoma (MTC), pheochromocytomas, and parathyroid tumors.</p>\n<p>MEN <strong>2B</strong> is characterised by MTC, pheochromocytoma, mucosal neuromas, marfanoid habitus, medullated corneal nerve fibres, and megacolon.</p>\n<p>MEN <strong>4</strong> is associated with parathyroid adenoma, pituitary adenoma, and <strong>reproductive organ tumors.</strong></p>\n<p>Other options</p>\n<p>Option B: <strong>Loss of function mutation </strong>of<strong> RET </strong>gene leads to<strong> Hirschprung disease.</strong></p><hr><h3>Related Pearl: MEN 1 Syndrome Features</h3><p>Chromosome <strong>11q13 / MEN1 </strong>gene</p>\n<p>Also known as <strong>Wermer&rsquo;s syndrome</strong></p>\n<p>Characteristic tumors seen in:</p>\n<ul>\n<li>Parathyroid adenoma &ndash; 90 % - Most common overall</li>\n<li>Entero pancreatic tumors - Most common functioning tumor is gastrinoma (most common site is duodenum)</li>\n<li>Pituitary adenoma &ndash; Most common is prolactinoma</li>\n<li><strong>Mnemonic</strong> &ndash; Par Pan Pit &ndash; in decreasing order of frequency</li>\n</ul>\n<p>Associated tumors are:</p>\n<ul>\n<li>Angiofibroma</li>\n<li>Collagenomas</li>\n<li>Adrenal cortical tumors</li>\n<li>Lipoma</li>\n<li>Neuroendocrine tumors - gastric, thymic, lungs</li>\n<li>Meningioma</li>\n<li>Pheochromocytoma</li>\n<li>Carcinoid tumors, usually of the foregut</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/95f7c4eac7794f728806926c4f50bbb2x1280x1061.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: MEN 2 Syndrome Features</h3><p><strong>MEN 2A</strong></p>\n<ul>\n<li>Known as <strong>Sipple&rsquo;s</strong> syndrome</li>\n<li>Chromosome <strong>10</strong> / <strong>RET gene</strong></li>\n<li>Associated conditions are:\n<ul>\n<li>Medullary Thyroid Carcinoma (90%)</li>\n<li>Pheochromocytoma (&gt;50%)</li>\n<li>Parathyroid adenoma (10&ndash;25%)</li>\n</ul>\n</li>\n</ul>\n<p><strong>MEN 2B</strong></p>\n<ul>\n<li>Known commonly as<strong> MEN 3</strong></li>\n<li>Chromosome<strong> 10/ RET gene</strong></li>\n<li>Associated conditions are:\n<ul>\n<li>Medullary Thyroid Carcinoma (&gt;90%)</li>\n<li>Pheochromocytoma (&gt;50%)</li>\n<li>Other associated abnormalities include: (40&ndash;50%)\n<ul>\n<li>Mucosal neuromas</li>\n<li>Marfanoid habitus</li>\n<li>Medullated corneal nerve fibers</li>\n<li>Megacolon</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a01742751e314b5fb189a29264e911d3x1280x1061.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: Cancers associated with important oncogenes</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Oncogenes</strong></p>\n</td>\n<td><strong>Associated cancers</strong></td>\n</tr>\n<tr>\n<td>\n<p><em>c-MYC</em></p>\n</td>\n<td>\n<p>Burkitt&rsquo;s lymphoma</p>\n<p>Adenocarcinomas of the breast, lung, and colon</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>N-MYC</em></p>\n</td>\n<td>\n<p>Neuroblastoma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>L-MYC</em></p>\n</td>\n<td>\n<p>Small-cell carcinoma of the lung</p>\n</td>\n</tr>\n<tr>\n<td><em>K-RAS</em></td>\n<td>Colon, lung, and pancreatic tumors</td>\n</tr>\n<tr>\n<td><em>N-RAS</em></td>\n<td>\n<p>Melanoma</p>\n<p>AML</p>\n</td>\n</tr>\n<tr>\n<td><em>H-RAS</em></td>\n<td>Bladder and kidney tumors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/e31505be1cbb411781f75172bbd94af0.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG0047",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements regarding tumour markers is false?",
      "choices": [
        {
          "id": 1,
          "text": "Biological and analytical variability are some of the commonly encountered disadvantages of tumour markers"
        },
        {
          "id": 2,
          "text": " No existing tumor biomarker possesses high accuracy for prognostic indication"
        },
        {
          "id": 3,
          "text": "Tumor markers have the sensitivity but not the specificity to diagnose cancers"
        },
        {
          "id": 4,
          "text": "Serum levels of AFP and CEA can be elevated in a variety of non-neoplastic conditions, limiting their value as screening tests"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Statement 3</strong> is a false statement regarding tumour markers.</p>\n<p>Biochemical assays for tumour-associated enzymes, hormones, and other tumour markers may aid in cancer diagnosis. They are also frequently helpful in tracking a tumour's response to treatment and identifying tumour recurrence. Nevertheless, they <strong>do not have</strong> both the <strong>sensitivity</strong> and <strong>specificity </strong>required to diagnose cancer.</p>\n<p><strong>Tumour biomarkers</strong> are substances synthesised by cancer cells or other body cells in response to cancer and released into circulation. </p>\n<p>The <strong>structural</strong> <strong>makeup</strong> of tumour biomarkers varies greatly. They can be simple molecules like <strong>catecholamines</strong> or well-characterized <strong>proteins</strong> like <strong>hormones</strong>, <strong>enzymes</strong>, or more diverse <strong>glycoproteins</strong> or <strong>mucins</strong> like carbohydrate antigen 125 (CA-125), which can be measured by antibodies. Alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and human chorionic gonadotropin (hCG) are examples of significant tumour biomarkers that are oncofetal <strong>antigens</strong> that are present in a normal foetus and are expressed at low levels by healthy tissues but at high concentrations by certain malignancies.</p>\n<p><strong>Disadvantages</strong> of tumour markers are:</p>\n<ul>\n<li>No existing tumour biomarker possesses high specificity, sensitivity, accuracy and reproducibility rates, offering cost-effective screening, diagnosis, and <strong>prognostic indication</strong>.</li>\n<li>Tumor markers cannot be used as standalone diagnostic markers for malignancies. <strong>Biological</strong> and <strong>analytical variability</strong> limit their usage. For example, tumour markers such as AFP are found to be elevated in non-neoplastic conditions like liver diseases. Another example is CEA which is elevated in conditions like ulcerative colitis, pancreatitis, etc. Hence, relying entirely on tumour biomarker assays may lead to <strong>inaccurate</strong> or <strong>incomplete</strong> <strong>diagnostic</strong> <strong>conclusions</strong>.</li>\n</ul>\n<p><span>Therefore, it is pivotal for us to make use of the tumour markers along with other diagnostic methods (imaging studies, biopsies, or clinical evaluations) to establish a comprehensive diagnosis.</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG7156",
      "difficulty": "hard"
    },
    {
      "text": "A 42-year-old woman who presented with a 3-month history of a painless firm lump in her breast's upper outer quadrant underwent breast conservative surgery and is now awaiting instructions on follow-up. What is the recommended advice regarding the follow-up for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Annual mammograms of the treated and contralateral breast"
        },
        {
          "id": 2,
          "text": "Annual mammograms of the contralateral breast only"
        },
        {
          "id": 3,
          "text": "Annual mammograms of the contralateral breast only and Serum tumor markers"
        },
        {
          "id": 4,
          "text": "Annual mammograms of the treated and contralateral breast and Serum tumor markers"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>For a patient with the given clinical scenario after treatment of breast cancer, the recommended follow-up advice consists of a routine physical examination once in 3 months for the first two years<strong> </strong>and<strong> annual mammograms of the treated and contralateral breast.</strong></p>\n<p><strong>Mammography is the only imaging</strong> modality necessary for follow-up after breast cancer surgery. There is currently <strong>no role for tumour markers</strong>, serum investigations, or any other imaging studies like bone scans in follow-up.</p>\n<p>Women who have had a <strong>mastectomy</strong>, including simple mastectomy, modified radical mastectomy, and radical mastectomy would <strong>not need further routine screening mammograms on that side</strong>, but will still need to have a <strong>yearly mammogram</strong> on the remaining breast.</p>\n<p>The guidelines for follow-up are as follows,</p>\n<p><strong>Physical examination:</strong></p>\n<ul>\n<li>For the <strong>first 2 years:</strong><span> once every</span><strong> 3 </strong><span>months</span></li>\n<li>For<strong> 3-5 years:</strong> once every <strong>6 </strong>months</li>\n<li><strong>After 5 </strong>years: <strong>Annually</strong></li>\n</ul>\n<p><strong>Mammography: </strong>Annually</p><hr><h3>Related Pearl: Important surgeries for breast cancer</h3><ul>\n<li>Tylectomy:&nbsp;Excision of lump</li>\n<li><strong>Breast conservation surgery (BCS)/WLE (wide local excision)</strong>: Tumour removal with a 3D clearance of a 1 mm margin of normal tissue</li>\n<li><strong>Simple mastectomy:</strong>&nbsp;Palpable extent of breast +&nbsp;Nipple&ndash;areola complex + overlying skin.</li>\n<li>Extended simple mastectomy: Simple mastectomy + removal of level I axillary lymph nodes.</li>\n<li>Skin-sparing mastectomy: Mastectomy with breast envelope preservation and nipple-areola complex removal</li>\n<li>Skin+ nipple/areola-sparing mastectomy: Mastectomy with breast envelope and nipple-areola complex preservation</li>\n<li><strong>Total mastectomy:</strong>&nbsp;All breast tissue + Nipple&ndash;areola complex + skin.</li>\n<li><strong>Level I oncoplasty (volume displacement surgery):</strong> Tumour excision with wide margins followed by defect repair via dual-plane mobilisation of the breast parenchyma to maintain shape and symmetry</li>\n<li><strong>Level II oncoplasty (volume replacement surgery):</strong> Skin excision and glandular mobilisation involving &gt;20% resection of breast volume</li>\n<li><strong>Modified radical mastectomy:</strong>&nbsp; Entire breast tissue + Nipple&ndash;areola complex + skin + axillary lymph nodes (levels I + II &plusmn; III) dissection\n<ul>\n<li><strong>Patey&rsquo;s:</strong> Pectoralis minor is removed</li>\n<li><strong>Scanlon&rsquo;s</strong>: Pectoralis minor incised</li>\n<li><strong>Auchincloss</strong>: Pectoralis minor only retracted</li>\n</ul>\n</li>\n<li><strong>Halsted&rsquo;s radical mastectomy:</strong>&nbsp;Entire breast tissue + Nipple&ndash;areola complex + skin + Levels I + II+ III Axillary lymph nodes + Pectoralis major and minor</li>\n<li>Extended radical (Urban) - Halsted&rsquo;s + internal mammary lymph nodes dissection</li>\n<li>Extended radical (Dahl-Iverson) mastectomy: Halsted&rsquo;s + internal mammary and supraclavicular lymph nodes dissection</li>\n<li>Super radical mastectomy: Halsted&rsquo;s + internal mammary, supraclavicular and mediastinal lymph nodes dissection.</li>\n</ul>\n<p>*Dual-plane mobilisation of breast parenchyma: Mobilisation of the dermoglandular plane and plane between breast parenchyma and pectoralis muscle.</p><hr><h3>Related Pearl: Hormonal therapy in breast carcinoma given for ER/PR-positive cases</h3><p><strong>Role:</strong></p>\n<ul>\n<li>Reduce risk of recurrence</li>\n<li>Reduce risk of contralateral breast cancer</li>\n<li>Reduce risk of progression of in situ to invasive carcinoma</li>\n</ul><table>\n<tbody>\n<tr>\n<td>Selective estrogen- receptor modulator</td>\n<td>Aromatase inhibitors</td>\n<td>Ovarian suppression/ ablation</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Tamoxifen</li>\n<li>Raloxifen</li>\n<li>Arzoxifen</li>\n<li>Fenoxifen</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Anastrazole</li>\n<li>Letrozole</li>\n<li>Exemestane</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Oophorectomy</li>\n<li>GnRH analogues</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8438",
      "difficulty": "medium"
    },
    {
      "text": "A 55-year-old man presents with vague abdominal pain for the last six months, and a recent blood investigation revealed elevated levels of serum CEA and CA 19-9. He also noticed spontaneously appearing and disappearing tender nodules (clots) under the skin at different locations, as shown below. Which of the other following conditions is most likely associated with his skin lesions?",
      "choices": [
        {
          "id": 1,
          "text": "Deep venous thrombosis"
        },
        {
          "id": 2,
          "text": "Buerger's disease"
        },
        {
          "id": 3,
          "text": "Raynaud's phenomenon"
        },
        {
          "id": 4,
          "text": "Takayasu arteritis"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Buerger's disease</strong> is the other condition among the given options that is associated with the given skin lesions.</p>\n<p>This patient with vague abdominal pain, elevated serum markers of CA19-9 and CEA, and skin showing features of migratory thrombophlebitis are consistent with a diagnosis of <strong>pancreatic carcinoma</strong>. Patients with<strong> Buerger’s disease </strong>can also present with <strong>migratory thrombophlebitis</strong>.</p>\n<div class=\"page\" title=\"Page 1001\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Buerger’s disease is a progressive <strong>non-atherosclerotic segmental inflammatory disease</strong> that most often affects small- and medium-sized arteries, veins, and nerves of the upper and lower extremities.</p>\n<div class=\"page\" title=\"Page 1001\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Clinical features:</p>\n<ul>\n<li>Typically presents in <strong>young male smokers</strong>, with symptoms beginning before<strong> age 40</strong>.</li>\n<li>Patients initially present with foot, leg, arm, or hand <strong>claudication,</strong> which may progress to rest pain to calf claudication and eventually ischemic <strong>rest pain</strong> and <strong>ulcerations</strong> on the toes, feet, fingers and even <strong>gangrene.</strong></li>\n<li>A complete history should exclude diabetes, hyperlipidemia, or autoimmune disease as possible etiologies for the occlusive lesions.</li>\n</ul>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<p>Pathogenesis:</p>\n<p>Smoking increases the level of carboxyhemoglobin, which causes <strong>vasospasm and hyperplasia of the intima</strong> of small and medium-sized vessels. This eventually results in thrombosis and obliteration of vessels, followed by <strong>segmental pan arteritis</strong>. Eventually, the artery, vein, and nerve are together involved, which causes rest pain (nerve involvement) and ischemia in the limb (arterial involvement).</p>\n<p>Once blockage occurs, plenty of collaterals open up depending on the site of blockage to maintain blood supply to the ischaemic area, resulting in a <strong>compensatory peripheral vascular disease</strong>. If the patient continues to smoke, the disease progresses into the collaterals, blocking them eventually, leading to severe ischemia, which is called <strong>decompensatory peripheral vascular disease</strong>.</p>\n<p>It is presently called <strong>critical limb ischemia.</strong> It causes rest pain, ulceration, and gangrene.</p>\n<p>Investigations:</p>\n<ul>\n<li aria-level=\"1\">Arterial<strong> doppler </strong>and <strong>duplex</strong> scan (Doppler + B mode U/S)</li>\n<li aria-level=\"1\"><strong>Transfemoral retrograde angiogram</strong> through Seldinger technique</li>\n<li aria-level=\"1\">Characteristic angiographic findings show disease confinement to the distal circulation, usually infra popliteal and distal to the brachial artery. The occlusions are segmental and show <strong>“skip” lesions</strong> with extensive collateralisation, the so-called <strong>corkscrew collaterals.</strong></li>\n</ul>\n<p>Treatment:</p>\n<ul>\n<li aria-level=\"1\"><strong>Cessation of smoking</strong> is the definitive management. </li>\n<li aria-level=\"1\">Drugs to improve circulation include\n<ul>\n<li aria-level=\"1\">Pentoxifylline</li>\n<li aria-level=\"1\">Aspirin</li>\n<li aria-level=\"1\">Clopidogrel</li>\n<li aria-level=\"1\">Statins </li>\n<li aria-level=\"1\">Cilostazol- Phosphodiesterase inhibitor is ideally used to improve circulation in the collaterals formed.</li>\n<li aria-level=\"1\"><strong>Vasodilators and anticoagulants have no role in the treatment.</strong></li>\n</ul>\n</li>\n<li aria-level=\"1\">Care of limb with Buerger’s exercise and positioning </li>\n<li aria-level=\"1\">Surgical management may include lumbar sympathectomy and amputation according to the presenting features. </li>\n</ul>\n<p>Other options</p>\n<p>Option A: <strong>Deep</strong> <strong>vein</strong> <strong>thrombosis</strong> (DVT) is a pathological condition characterised by the obstruction of blood flow in the deep veins, resulting from impaired venous reflux mechanism. <strong>DVT</strong> is <strong>not</strong> associated with <strong>migratory</strong> <strong>thrombophlebitis</strong>.</p>\n<p>Option C: <strong>Raynaud</strong> <strong>phenomenon</strong> is manifested as episodic vasoconstriction of the arteries and arterioles of the extremities, causing pallor of extremities followed by pain and cyanosis. It is seen in virtually all patients with systemic sclerosis or scleroderma and precedes other symptoms in 70% of cases. <strong>Raynaud</strong> <strong>phenomenon</strong> is <strong>not</strong> associated with <strong>migratory thrombophlebitis</strong>.</p>\n<p>Option D: <strong>Takayasu</strong> <strong>arteritis</strong> is the inflammation of the medium to <strong>large-sized arteries</strong>. It mainly affects the aortic arch and its branches. The most commonly affected artery is the subclavian artery. Patients will present with features of arm claudication, Raynaud's phenomenon, etc. They can also present with syncope, transient ischemic attack, abdominal pain, or chest pain, depending on the arteries involved. A biopsy of the affected artery will show <strong>pan</strong> <strong>arteritis</strong> with <strong>mononuclear</strong> <strong>cell</strong> <strong>infiltrates</strong> and occasionally giant cells. <strong>Takayasu</strong> <strong>arteritis</strong> is <strong>not</strong> associated with <strong>migratory</strong> <strong>thrombophlebitis</strong>.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/615500ddbcb6413d94c526f16e387773.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG0652",
      "difficulty": "hard"
    },
    {
      "text": "TP53 mutants can be discovered in the serum in all the following cancers except?",
      "choices": [
        {
          "id": 1,
          "text": "Colon Cancer"
        },
        {
          "id": 2,
          "text": "Lung Cancer"
        },
        {
          "id": 3,
          "text": "Pancreatic Cancer"
        },
        {
          "id": 4,
          "text": "Bladder Cancer"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>In <strong>Bladder Cancer, </strong>TP53 mutants are found in<strong> Urine, </strong>and not in serum.</p>\n<p>Meanwhile, <strong>Cell-Free DNA markers</strong> such as <strong>TP53 mutants</strong> are found in the serum in Colon, Lung and Pancreatic cancers.</p><hr><h3>Related Pearl: Tumor Markers</h3><p><strong>Tumor Markers</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Tumor Markers</strong></p>\n</td>\n<td>\n<p><strong>Tumor Types</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Hormones</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Human chorionic gonadotropin</p>\n</td>\n<td>\n<p>Trophoblastic tumors, nonseminonmatous testicular tumors</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Calcitonin</p>\n</td>\n<td>\n<p>Medullary carcinoma of thyroid</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Catecholamine and metabolites</p>\n</td>\n<td>\n<p>Pheochromocytoma and related tumors</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Oncofetal Antigens</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&alpha;-Fetoprotein</p>\n</td>\n<td>\n<p>Liver cell cancer, nonseminonmatous germ-cell tumors of the&nbsp;testis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Carcinoembryonic antigen</p>\n</td>\n<td>\n<p>Carcinomas of the colon, lung, stomach, and heart</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Enzymes</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Prostatic acid phosphatase</p>\n</td>\n<td>\n<p>Prostate cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Neuron-specific enolase</p>\n</td>\n<td>Small-cell cancer of the lung, neuroblastoma</td>\n</tr>\n<tr>\n<td>\n<p>Lactate dehydrogenase (LDH)</p>\n</td>\n<td>Germ-cell tumors, lymphomas, leukemias</td>\n</tr>\n<tr>\n<td>Thymidine kinase</td>\n<td>Leukemias</td>\n</tr>\n<tr>\n<td>Pyruvate kinase</td>\n<td>Renal cell carcinoma</td>\n</tr>\n<tr>\n<td>Placental alkaline phosphatase</td>\n<td>Seminoma</td>\n</tr>\n<tr>\n<td>\n<p><strong>Specific Proteins</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Immunoglobulins</p>\n</td>\n<td>\n<p>Multiple myeloma and other gammopathies</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Prostate-specific antigen and prostate- specific membrane antigen</p>\n</td>\n<td>\n<p>Prostate cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>NMP 22</p>\n</td>\n<td>\n<p>Bladder cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Mucins and Other Glycoproteins</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>CA-125</p>\n</td>\n<td>\n<p>Ovarian cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>CA- 19-9</p>\n</td>\n<td>\n<p>Colon cancer, pancreatic cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>CA-15-3</p>\n</td>\n<td>\n<p>Breast cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Cell-Free DNA markers</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53, APC, RAS</em> mutants in stool and serum</p>\n</td>\n<td>\n<p>Colon cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53, RAS</em> mutants in stool and serum</p>\n</td>\n<td>\n<p>Pancreatic cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53, RAS</em> mutants in sputum and serum</p>\n</td>\n<td>\n<p>Lung cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53</em> mutants in urine</p>\n</td>\n<td>\n<p>Bladder cancer</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>NMP: Nuclear matrix protein</p>\n<p>CA: Carbohydrate antigen</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4495",
      "difficulty": "medium"
    },
    {
      "text": "Match the following tumor markers with their malignancies:<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>1. Alpha-fetoprotein</td>\n<td>a. Colon cancer</td>\n</tr>\n<tr>\n<td>2. Calretinin</td>\n<td>b. Epithelial ovarian cancer</td>\n</tr>\n<tr>\n<td>3. Carcinoembryonic antigen</td>\n<td>c. Mesothelioma</td>\n</tr>\n<tr>\n<td>4. CA-125</td>\n<td>d. Liver cell cancer</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1-d, 2-a, 3-b, 4-c"
        },
        {
          "id": 2,
          "text": "1-c, 2-d, 3-b, 4-a"
        },
        {
          "id": 3,
          "text": "1-a, 2-c, 3-b, 4-d"
        },
        {
          "id": 4,
          "text": "1-d, 2-c, 3-a, 4-b"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The correctly matched pair of tumor markers and their malignancies is <strong>1-d, 2-c, 3-a,</strong> and<strong> 4-b</strong> (option D).</p>\n<table>\n<tbody>\n<tr>\n<td>Tumor markers</td>\n<td> Malignancies</td>\n</tr>\n<tr>\n<td>1. Alpha-fetoprotein</td>\n<td>\n<p>d. Liver cell cancer</p>\n</td>\n</tr>\n<tr>\n<td>2. Calretinin</td>\n<td>c. Mesothelioma</td>\n</tr>\n<tr>\n<td>\n<p>3. Carcinoembryonic antigen</p>\n</td>\n<td>a. Colon cancer </td>\n</tr>\n<tr>\n<td>4. CA-125</td>\n<td>b.  Epithelial ovarian cancer</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Tumor Markers</h3><p><strong>Tumor Markers</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Tumor Markers</strong></p>\n</td>\n<td>\n<p><strong>Tumor Types</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Hormones</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Human chorionic gonadotropin</p>\n</td>\n<td>\n<p>Trophoblastic tumors, nonseminonmatous testicular tumors</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Calcitonin</p>\n</td>\n<td>\n<p>Medullary carcinoma of thyroid</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Catecholamine and metabolites</p>\n</td>\n<td>\n<p>Pheochromocytoma and related tumors</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Oncofetal Antigens</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&alpha;-Fetoprotein</p>\n</td>\n<td>\n<p>Liver cell cancer, nonseminonmatous germ-cell tumors of the&nbsp;testis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Carcinoembryonic antigen</p>\n</td>\n<td>\n<p>Carcinomas of the colon, lung, stomach, and heart</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Enzymes</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Prostatic acid phosphatase</p>\n</td>\n<td>\n<p>Prostate cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Neuron-specific enolase</p>\n</td>\n<td>Small-cell cancer of the lung, neuroblastoma</td>\n</tr>\n<tr>\n<td>\n<p>Lactate dehydrogenase (LDH)</p>\n</td>\n<td>Germ-cell tumors, lymphomas, leukemias</td>\n</tr>\n<tr>\n<td>Thymidine kinase</td>\n<td>Leukemias</td>\n</tr>\n<tr>\n<td>Pyruvate kinase</td>\n<td>Renal cell carcinoma</td>\n</tr>\n<tr>\n<td>Placental alkaline phosphatase</td>\n<td>Seminoma</td>\n</tr>\n<tr>\n<td>\n<p><strong>Specific Proteins</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Immunoglobulins</p>\n</td>\n<td>\n<p>Multiple myeloma and other gammopathies</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Prostate-specific antigen and prostate- specific membrane antigen</p>\n</td>\n<td>\n<p>Prostate cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>NMP 22</p>\n</td>\n<td>\n<p>Bladder cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Mucins and Other Glycoproteins</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>CA-125</p>\n</td>\n<td>\n<p>Ovarian cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>CA- 19-9</p>\n</td>\n<td>\n<p>Colon cancer, pancreatic cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>CA-15-3</p>\n</td>\n<td>\n<p>Breast cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Cell-Free DNA markers</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53, APC, RAS</em> mutants in stool and serum</p>\n</td>\n<td>\n<p>Colon cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53, RAS</em> mutants in stool and serum</p>\n</td>\n<td>\n<p>Pancreatic cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53, RAS</em> mutants in sputum and serum</p>\n</td>\n<td>\n<p>Lung cancer</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><em>TP53</em> mutants in urine</p>\n</td>\n<td>\n<p>Bladder cancer</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>NMP: Nuclear matrix protein</p>\n<p>CA: Carbohydrate antigen</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG7175",
      "difficulty": "easy"
    },
    {
      "text": "A 14-year-old boy presents with pain in the right leg accompanied by symptoms of fever and fatigue. His X-ray shows onion peel appearance with extension into the bone marrow. Which of the following is associated with this condition?",
      "choices": [
        {
          "id": 1,
          "text": "There is poor response to radio therapy"
        },
        {
          "id": 2,
          "text": "Stains positive for reticulin"
        },
        {
          "id": 3,
          "text": "The serum LDH is elevated"
        },
        {
          "id": 4,
          "text": "There is a t(12:21) translocation"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>This patient has pain in the limb with fever and fatigue with onion peel appearance on X-Ray with extension into the bone marrow<span>. This is most likely </span><strong>Ewing's sarcoma</strong><span>. It is associated with an</span><strong> elevated serum LDH.</strong></p>\n<p>Ewing sarcoma<strong> </strong>is the <strong>2nd most common</strong> bone sarcoma in children. The majority of the patients affected are usually <strong>&lt;20 years</strong> of age. It has a slight <strong>male</strong> <strong>predominance</strong>. The majority of Ewing sarcomas have a balanced translocation between the EWSR1 gene on <strong>chromosome 22</strong> and the FLI1 gene on <strong>chromosome 11</strong>. </p>\n<p>It commonly involves the <strong>diaphysis</strong> of the <strong>long bones</strong> like the <strong>femur</strong>,<strong> tibia</strong>, fibula, humerus, and <strong>flat bones</strong> of the <strong>pelvis</strong>. Patients present with <strong>painful enlarging mass</strong>, fever, and anemia. The affected area is usually tender, swollen, and warm.</p>\n<p>Laboratory findings may show an elevated WBC count, LDH levels (lactate dehydrogenase) and erythrocyte sedimentation rate (ESR). The common diagnostic test used for Ewing’s sarcoma is the detection of translocation <strong>t(11;22) (q24;q12)</strong>. </p>\n<p>A histopathological examination of Ewing sarcoma shows sheets of<strong> uniform, round blue cells </strong>arranged in<strong> Homer-Wright rosettes</strong>. Immunohistochemistry is usually positive for<strong> synaptophysin </strong>and<strong> mic-2</strong>. The tumor cells contain glycogen and are hence <strong>PAS positive </strong>and they are <strong>reticulin negative</strong>.</p>\n<p>Preoperative chemotherapy with <strong>vincristine</strong>,<strong> ifosfamide</strong>, <strong>doxorubicin</strong> and <strong>etoposide</strong> results in extensive tumor necrosis and shrinkage. <strong>Wide excision</strong> may be combined with <strong>adjuvant radiotherapy</strong> if surgical margins are poor. Definitive radiotherapy rather than surgical excision may be advocated if it is non-resectable or metastasis has occurred. It is a <strong>radio-sensitive</strong> tumor.</p>\n<p><strong>Indicators</strong> of <strong>poor prognosis</strong> in patients with Ewing's sarcoma:</p>\n<ul>\n<li>Presence of <strong>distant</strong> <strong>metastasis</strong> - <strong>worst</strong> <strong>prognostic</strong> <strong>factor</strong></li>\n<li>Size and location of the primary lesion</li>\n<li>Presence of fever, anemia</li>\n<li><strong>Leukocytosis</strong>, raised ESR. </li>\n</ul>\n<p>Other Options:</p>\n<p>Ewing's sarcoma is <strong>radio sensitive</strong>(Option A), reticulin negative(Option B) and associated with a t(11:22) (Option D) translocation.</p><hr><h3>Related Pearl: Important radiosenstive and radioresistant bone tumours</h3><p><strong>Radiosensitive</strong> tumors:</p>\n<ol>\n<li>Metastasis (except metastasis from renal cell carcinoma which is radioresistant)</li>\n<li>Ewing's sarcoma</li>\n<li>Multiple myeloma</li>\n<li>Lymphoma</li>\n</ol>\n<p><strong>Radioresistant</strong> tumors:</p>\n<ol>\n<li>Osteosarcoma</li>\n<li>Chondrosarcoma</li>\n<li>Fibrosarcoma</li>\n<li>Malignant fibrous histiocytoma</li>\n</ol><hr><h3>Related Pearl: Summary of Bone Tumors</h3><table>\n<tbody>\n<tr>\n<td><strong>Bone tumor</strong></td>\n<td><strong>Most common site</strong></td>\n<td><strong>Age</strong></td>\n</tr>\n<tr>\n<td>Simple bone cyst</td>\n<td>Proximal Humeral Metaphysis</td>\n<td>&lt;20years</td>\n</tr>\n<tr>\n<td>Enchondroma</td>\n<td>\n<p>Hand bones</p>\n<p>(Metaphysis of small bones of hand)</p>\n</td>\n<td>\n<p>4<sup>th</sup>&nbsp;&amp; 5<sup>th</sup></p>\n<p>Decade</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Osteochondroma</p>\n<p>(Exostosis)</p>\n</td>\n<td>Distal Femoral Metaphysis</td>\n<td>&lt;18years</td>\n</tr>\n<tr>\n<td>Osteoid osteoma</td>\n<td>Diaphysis of Femur</td>\n<td>\n<p>2<sup>nd</sup>&nbsp;&amp; 3<sup>rd</sup></p>\n<p>decade</p>\n</td>\n</tr>\n<tr>\n<td>Osteoblastoma</td>\n<td>Posterior column of vertebra</td>\n<td>\n<p>2<sup>nd</sup>&nbsp;&amp; 3<sup>rd</sup></p>\n<p>decade</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Osteoclastoma (GCT)</p>\n</td>\n<td>Distal femoral epiphysis</td>\n<td>\n<p>2<sup>nd</sup> -4<sup>th</sup></p>\n<p>Decade</p>\n</td>\n</tr>\n<tr>\n<td>Aneurysmal Bone Cyst</td>\n<td>Long bone Metaphysis</td>\n<td>&lt;18years</td>\n</tr>\n<tr>\n<td>Osteosarcoma</td>\n<td>Distal Femoral Metaphysis</td>\n<td>\n<p>BIMODAL</p>\n<p>Primary- 2<sup>nd</sup> Decade Secondary-6<sup>th</sup> and 7<sup>th</sup> Decade</p>\n</td>\n</tr>\n<tr>\n<td>Ewings sarcoma</td>\n<td>Diaphysis of Femur</td>\n<td>5-25 years</td>\n</tr>\n<tr>\n<td>Chondrosarcoma</td>\n<td>Any site in the bone - mc in proximal femur</td>\n<td>3<sup>rd</sup>-5<sup>th</sup> decade</td>\n</tr>\n<tr>\n<td>Clear cell chondrosarcoma</td>\n<td>Proximal femoral epiphysis</td>\n<td>&nbsp;3<sup>rd</sup>-5<sup>th</sup> decade</td>\n</tr>\n<tr>\n<td>Adamantinoma</td>\n<td>Diaphysis of Tibia</td>\n<td>&nbsp;20-40 years</td>\n</tr>\n<tr>\n<td>&nbsp;Fibrous dysplasia</td>\n<td>&nbsp;The upper end of femur &gt; tibia</td>\n<td>&nbsp;1st to 3rd decade</td>\n</tr>\n<tr>\n<td>&nbsp;Chordoma</td>\n<td>&nbsp;Sacrum</td>\n<td>&nbsp;5th to 7th decade</td>\n</tr>\n<tr>\n<td>Multiple myeloma</td>\n<td>Vertebrae</td>\n<td>5th to 7th decade</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><hr><h3>Related Pearl: Classical Radiological Appearance of Bone Tumors</h3><table>\n<tbody>\n<tr>\n<td><strong>RADIOLOGICAL APPEARANCE&nbsp;</strong></td>\n<td>\n<p><strong>TUMORS</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sunray appearance / Codman&rsquo;s triangle</p>\n</td>\n<td>\n<p>Osteosarcoma (but can be seen in any malignant lesion)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Onion peel appearance&nbsp;</p>\n</td>\n<td>\n<p>Ewing&rsquo;s sarcoma (but can be seen in any malignant lesion or chronic osteomyelitis)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Soap bubble appearance&nbsp;</p>\n</td>\n<td>\n<p>Giant cell tumor, adamantinoma&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Ground glass appearance / Shepherd's</p>\n<p>crook deformity&nbsp;</p>\n</td>\n<td>\n<p>Fibrous dysplasia&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Patchy calcification&nbsp;</p>\n</td>\n<td>\n<p>Chondrogenic tumors (chondrosarcoma and chondroblastoma)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Popcorn, punctate or comma-shaped calcification</p>\n</td>\n<td>\n<p>Chondrosarcoma&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Stippled or Punctate calcification</p>\n</td>\n<td>\n<p>Chondroblastoma&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Homogeneous calcification&nbsp;</p>\n</td>\n<td>\n<p>Osteogenic tumors (osteosarcoma)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Fallen fragment / Trap door sign</p>\n</td>\n<td>\n<p>Simple bone cyst</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Double-density fluid levels and intra-lesional septation</p>\n</td>\n<td>\n<p>Aneurysmal bone cyst</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Winking owl sign</p>\n</td>\n<td>\n<p>Vertebral metastasis&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Polka dot sign / Corduroy / Jailhouse sign</p>\n</td>\n<td>\n<p>Vertebral hemangioma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Moth eaten bone</p>\n</td>\n<td>\n<p>Multiple myeloma</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MG0186",
      "difficulty": "hard"
    },
    {
      "text": "An elderly woman presented with complaints of discoloration on her face. An excisional biopsy was done, and histopathology findings are shown below. They stain positive for HMB - 45. Which of the following statements is incorrect regarding her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Superficial spreading type is the most common variant"
        },
        {
          "id": 2,
          "text": "Mutation in the hedgehog signalling pathway"
        },
        {
          "id": 3,
          "text": "Mutation in receptor tyrosine kinase signalling pathway"
        },
        {
          "id": 4,
          "text": "Shows positive immunohistochemistry staining for S-100"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p class=\"p1\">The given history and histopathology showing <strong>dense intracytoplasmic brownish-black</strong> <strong>melanin pigment</strong> are suggestive of <strong>malignant melanoma</strong>. Mutations&nbsp;in the&nbsp;<strong>hedgehog signaling pathway</strong>&nbsp;are associated with <strong>basal cell carcinoma</strong> and not malignant melanoma.&nbsp;</p>\n<div class=\"ng-star-inserted\">\n<div class=\"table-responsive font-weight-light answer-scroll ng-star-inserted\">\n<p>Malignant melanoma&nbsp;primarily arises from&nbsp;<strong>melanocytes</strong>&nbsp;at the epidermal-dermal junction but may also originate from mucosal surfaces of the&nbsp;<strong>oropharynx, nasopharynx, eyes, proximal esophagus, anorectal, </strong>and <strong>female genitalia</strong>. It includes<strong>&nbsp;a pigmented lesion</strong>&nbsp;that has enlarged, ulcerated, or bled. Amelanotic lesions appear as raised pink, purple, or flesh-colored skin papules. The diagnostic clue for melanoma is the&nbsp;<strong>ABCDE</strong>&nbsp;criteria.</p>\n<p>It consists of</p>\n<ul>\n<li><strong>A</strong>symmetry</li>\n<li><strong>B</strong>order irregularity</li>\n<li><strong>C</strong>olor variegation</li>\n<li><strong>D</strong>iameter of more than 6 mm&nbsp;</li>\n<li><strong>E</strong>volution or change</li>\n</ul>\n<p>The image below shows a case of malignant melanoma.</p>\n</div>\n</div>\n<div class=\"ng-star-inserted\">\n<div class=\"ng-star-inserted\">\n<div class=\"h-400-scroll mb-2 ng-star-inserted\"><img class=\"img-fluid hover-max\" src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/506a8d63fc0d4accaa9d9ac8a0082518x720x963.JPEG\" /></div>\n</div>\n</div>\n<p class=\"p1\">Lentigo maligna, superficial spreading, acral lentiginous, and nodular are the variants of malignant melanoma<strong>. Superficial spreading melanoma</strong>&nbsp;is the&nbsp;<strong>most common</strong>&nbsp;variant (Option A) of malignant melanoma. It is more commonly seen on the&nbsp;<strong>trunk</strong>&nbsp;and&nbsp;<strong>proximal extremities</strong>. It usually arises from a&nbsp;<strong>pre-existing nevus</strong>&nbsp;after a chronic period of change in color and border.&nbsp;<strong>Mutations</strong>&nbsp;in&nbsp;<strong>cell cycle regulators</strong>,&nbsp;receptor&nbsp;<strong>tyrosine kinase</strong>&nbsp;signaling pathway (Option C), and those that&nbsp;<strong>activate telomerase</strong>&nbsp;are associated with&nbsp;<strong>melanomas</strong>.</p>\n<p>Markers for melanoma include:</p>\n<ul>\n<li><strong>S100&nbsp;</strong>(Option D)</li>\n<li>MELAN-A</li>\n<li>HMB (Human Melanoma Black)-45</li>\n</ul><hr><h3>Related Pearl: Clinical Findings suggestive of Melanoma</h3><p>The <strong>ABCDE of melanoma</strong> consists of the rules for the <strong>examination of a nevus</strong> to assess its malignant potential:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0ed26d31e9e545f382b79820c1440f1fx800x557.JPEG\" alt=\"Pearl Image\"><p><strong>A</strong> : <strong>A</strong>symmetry</p>\n<ul>\n<li>Melanoma lesions are irregular, or not symmetrical, in shape</li>\n</ul>\n<p><strong>B </strong>: <strong>B</strong>order irregular</p>\n<ul>\n<li>Melanoma lesions usually have irregular borders that are ill-defined</li>\n</ul>\n<p><strong>C</strong> :&nbsp;<strong>C</strong>olor variation</p>\n<ul>\n<li>The presence of multiple colors (blue, black, brown, tan, etc.) or the uneven distribution of color</li>\n</ul>\n<p><strong>D </strong>: <strong>D</strong>iameter &gt;6 mm</p>\n<ul>\n<li>Melanoma lesions are often greater than 6 millimeters in diameter (approximately the size of a pencil eraser)</li>\n</ul>\n<p><strong>E : E</strong>volution</p>\n<ul>\n<li>There is a change in the size, shape, symptoms (such as itching or tenderness), surface (especially bleeding), or color of a mole</li>\n</ul><hr><h3>Related Pearl: Breslow’s  Classification of Malignant Melanoma</h3><p>Breslow's classification of malignant melanoma:</p>\n<table class=\"wikitable\">\n<tbody>\n<tr>\n<th>Stage</th>\n<th>Depth</th>\n</tr>\n<tr>\n<td>Stage I</td>\n<td>&le;&nbsp;0.75mm</td>\n</tr>\n<tr>\n<td>Stage II</td>\n<td>0.76&nbsp;mm - 1.50mm</td>\n</tr>\n<tr>\n<td>Stage III</td>\n<td>1.51&nbsp;mm - 4 mm</td>\n</tr>\n<tr>\n<td>Stage IV</td>\n<td>&gt;4 mm<sup id=\"cite_ref-pmid5477666_1-1\" class=\"reference\"></sup></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>TNM staging based on the thickness of invasion according to AJCC:</p>\n<div class=\"page\" title=\"Page 754\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>T1 - &le;1.0 mm</li>\n<li>T2 - 1.01-2.0 mm</li>\n<li>T3 - 2.01-4.0 mm</li>\n<li>T4 - &gt;4.0 mm</li>\n</ul>\n</div>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/42b06a5ff91d479b80343a49d7fe388ax1280x1019.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: Main Prognostic Factors for Primary Melanoma</h3><p>The following are the prognostic factors for primary melanoma (predictive value from *** high to * low):</p>\n<ul>\n<li>Thickness <strong>(Breslow index)</strong>***</li>\n<li><strong>Sentinel node</strong> status***</li>\n<li><strong>Ulceration</strong>**</li>\n<li><strong>Mitotic</strong> <strong>rate</strong>** (negative value especially in thin tumours)</li>\n<li>Regression* (underestimation of Breslow)</li>\n<li>Age* (negative for older age)</li>\n<li>Sex* (negative for males)</li>\n<li>Location* (negative for head and neck)</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/c2c32da7588c411a9fa43b6c29c36b89.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8536",
      "difficulty": "medium"
    },
    {
      "text": "An 8-year-old child presented with unilateral proptosis. CT scan of the orbit shows poorly defined mass with homogenous density with adjacent bony destruction. Histopathology is shown below. The immunohistochemistry of the cells was Desmin positive. What is the probable diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Neuroblastoma"
        },
        {
          "id": 2,
          "text": "Retinoblastoma"
        },
        {
          "id": 3,
          "text": "Rhabdomyosarcoma"
        },
        {
          "id": 4,
          "text": "Medulloblastoma"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical vignette and histopathology are suggestive of <strong>Rhabdomyosarcoma.</strong></p>\n<p>Rhabdomyosarcomas are the common soft tissue sarcomas of childhood and adolescence that may occur at virtually any anatomic site but are usually found in the <strong>head and neck (25%)</strong>, genitourinary tract (24%), extremities (19%), and orbit (9%). Retroperitoneum and other sites account for the remainder of primary sites.</p>\n<p>It is classified into three subtypes: alveolar, embryonal, and pleomorphic.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type</strong></td>\n<td><strong>Histopathology</strong></td>\n</tr>\n<tr>\n<td>Embryonal </td>\n<td>\n<p>Tumour consists of sheets of both <strong>primitive round and spindled cells</strong> in a myxoid stroma.</p>\n <strong>Sarcoma botryoid</strong> is a variant that occurs in the walls of hollow, mucosal-lined structures, such as the nasopharynx, common bile, bladder, and vagina.</td>\n</tr>\n<tr>\n<td>Alveolar </td>\n<td>Tumour consists of a network of <strong>fibrous septae</strong> that divide the cells into clusters or aggregates, creating a crude resemblance to pulmonary alveoli. </td>\n</tr>\n<tr>\n<td>Pleomorphic</td>\n<td>Tumour consists of large, sometimes multinucleated, <strong>bizarre eosinophilic tumour</strong> cells.<br /><br /></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br />Clinically, the tumour is usually <strong>aggressive</strong>, with unilateral proptosis when the orbit is involved. Swelling and redness of the overlying skin, diplopia may be present.</p>\n<p><br />In <strong>immunohistochemistry</strong>, they are positive for<strong> </strong></p>\n<ul>\n<li><strong>Desmin</strong> </li>\n<li>Myoglobin</li>\n<li>Myogenin</li>\n<li>MyoD1</li>\n<li>Vimentin.</li>\n</ul>\n<p>Pleomorphic rhabdomyosarcoma is seen predominantly in adults.</p>\n<p>Rhabdomyosarcoma shows a strong tendency for <strong>local invasion</strong>, local recurrence, and <strong>hematogenous</strong> and <strong>lymphatic</strong> metastases.</p>\n<p>Decision-making for management is based on <strong>histopathologic </strong>confirmation as well as the <strong>staging</strong> of orbital RMS, which includes imaging (MRI of primary tumour, chest-CT, Tc bone scan), pathology, and work-up for metastases(bone marrow biopsy)</p>\n<ul>\n<li aria-level=\"1\">Group I: Localized disease, completely resected (excisional biopsy).</li>\n<li aria-level=\"1\">Group II: Microscopic disease remaining after biopsy.</li>\n<li aria-level=\"1\">Group III: Gross residual disease remaining after biopsy.</li>\n<li aria-level=\"1\">Group IV: Distant metastasis present at onset.</li>\n</ul>\n<p>The below image shows the histopathology of Orbital Rhabdomyosarcoma.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c8412a2256a24f59bf2cbda047c8cbc2x512x740.PNG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/91229440a5c546c8bacb4a99ec910d13.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4728",
      "difficulty": "medium"
    }
  ]
}